Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan and HAART vs HAART Alone for HIV-Associated Nephropathy
NCT00089518Phase 3Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HIV-associated nephropathy (HIVAN) comparing Valsartan + ART with Placebo + ART (2 arms). Primary endpoint: Progression of Kidney Disease at 96 weeks. Status: withdrawn.
02
Drugs
valsartan
03
Conditions
HIV-associated nephropathy (HIVAN)
Beyond the preview
Go deeper on NCT00089518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089518.